23 August 2018
Visiongain’s new report Global Vaccine Contract Manufacturing Market Report 2017-2027: Leading Countries, Technologies and Companies indicates that the global vaccine contract manufacturing market will see $1251m in spending in 2021.
The global vaccine contract manufacturing market is expected to grow at a CAGR of 8.9% from 2016-2021 and CAGR of 9.2% from 2021-2027. The market is expected to grow at a CAGR of 9.1% from 2016 to 2027. The market is estimated at $816m in 2016, and $2117m in 2027.
The lead analyst of the report said: “The vaccine manufacturing technology and services market has experienced considerable growth over the past decade. Vaccines are a global healthcare success, currently driven by disease burden and the expanding global population. Paediatric vaccines will continue to be the leading market segment. Strong growth will be seen in the therapeutic vaccines market, driven by development of vaccines for indications such as cancer. Our research suggests that demand and technological developments in this industry will drive changes in the methods and management of vaccine production. The global vaccine market will experience strong growth throughout the forecast period, as will that for outsourced vaccine manufacturing.
Vaccine manufacturing is highly technical with stringent regulatory and quality standards which have mainly kept it within regions which have the technology and regulatory framework to accommodate production. Although off-shoring to lower costs is very popular for other industries, the vaccine contract manufacturing market in emerging markets will mainly show growth through domestic demands, at least in the first half of the forecast period, as emerging markets still grapples with international vaccine manufacturing practises and new technology platforms.”
The 155-page report contains 74 charts that add visual analysis in order to explain the developing trends within the Global Vaccine Contract Manufacturing market.
The report provides revenue and growth forecasts to 2027 as well as qualitative analyses for the global vaccine contract manufacturing market
This report also provides revenue forecasts for the period 2017-2027 as well as qualitative analyses for the global vaccine market and market shares of the submarkets: paediatric vaccines, adult vaccines, influenza vaccines and therapeutic vaccines.
The 155-page report offers market forecasts for the United States (US), Germany, France, the United Kingdom, Italy, Spain, Japan, China, India, Brazil, Russia and Rest of the World.
The report Global Vaccine Contract Manufacturing Market Report 2017-2027: Leading Countries, Technologies and Companies report will be of value to anyone who wants to better understand the vaccine contract manufacturing market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the vaccine contract manufacturing market.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
21 July 2021
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
20 July 2021
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.
14 July 2021
Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.